Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.

CEO

Country

France

ISIN

FR0010259150

Listings

0 Comments

Share your thoughts

FAQ

What is Ipsen stock price today?▼

The current price of I7G.MU is €162.40 EUR — it has increased by +0.31% in the past 24 hours. Watch Ipsen stock price performance more closely on the chart.

What is Ipsen stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Ipsen stocks are traded under the ticker I7G.MU.

Is Ipsen stock price growing?▼

I7G.MU stock has risen by +1.69% compared to the previous week, the month change is a +3.44% rise, over the last year Ipsen has showed a +53.64% increase.

What is Ipsen market cap?▼

Today Ipsen has the market capitalization of 13.61B

When is the next Ipsen earnings date?▼

Ipsen is going to release the next earnings report on July 30, 2026.

What were Ipsen earnings last quarter?▼

I7G.MU earnings for the last quarter are 5.96 EUR per share, whereas the estimation was 5.47 EUR resulting in a +8.93% surprise. The estimated earnings for the next quarter are N/A EUR per share.

What is Ipsen revenue for the last year?▼

Ipsen revenue for the last year amounts to 3.68B EUR.

What is Ipsen net income for the last year?▼

I7G.MU net income for the last year is 443.5M EUR.

Does Ipsen pay dividends?▼

Yes, I7G.MU dividends are paid annual. The last dividend per share was 1.6 EUR. As of today, Dividend Yield (FWD)% is 0.99%.

In which sector is Ipsen located?▼

Ipsen operates in the Materials sector.

When did Ipsen complete a stock split?▼

Ipsen has not had any recent stock splits.